FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2011-01-04** | Period of Report: **2011-01-04**
SEC Accession No. 0001157523-11-000035

FILER

RESPONSE BIOMEDICAL CORP
CIK:**806888**| IRS No.: **000000000** | State of Incorp.:**A1** | Fiscal Year End: **1231**
Type: **6-K** | Act: **34** | File No.: **000-50571** | Film No.: **11503319**
SIC: **8734** Testing laboratories

Mailing Address
1781 - 75TH AVENUE W.
VANCOUVER A1 V6P6P2

Business Address
1781 - 75TH AVENUE W.
VANCOUVER A1 V6P6P2
604-456-6010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2011

Commission File Number: **000-50571**

RESPONSE BIOMEDICAL CORP.

(Translation of registrant's name into English)

1781 - 75th Avenue W.
Vancouver, British Columbia, Canada V6P 6P2
(604) 456-6010
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

99.1 News Release dated 4 January 2011

99.2 Material Change Report 4 January 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Response Biomedical Corp.
(Registrant)

Date: January 4, 2011

By: */s/ L. Kaler*

Name: Livleen Kaler
Title: Chief Financial Officer

Exhibit 99.1

Response Biomedical Corporation Enters Into Exclusive Italian Distribution Agreement with Cremascoli & Iris, s.r.l.

VANCOUVER, British Columbia--(BUSINESS WIRE)--January 4, 2011--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that it has entered into an exclusive distribution agreement with Cremascoli & Iris, s.r.l. of Milan, Italy to distribute the full line of RAMP® cardiac products in Italy.

Italy is the second largest market in Europe after Germany for cardiac Point of Care Testing (POCT). The Italian market for POCT cardiac products is expected to exceed U.S. $50 million in 2011, and projected to grow at 5% per year through 2015. There are approximately 750 public hospitals and 400 private clinics throughout Italy.

“We are very pleased to be representing the RAMP® cardiac products in Italy,” said Andrea Cremascoli, Product Manager, POCT. “Due to the excellent product performance of the RAMP® products, we believe the Italian market offers significant opportunity for product placement and market growth in the coming years.”

“We are aggressively working to expand our market presence throughout Europe, the Middle East and Asia, and are delighted that Cremascoli will represent our RAMP® products in Italy,” said S. Wayne Kay, CEO, Response Biomedical. “Cremascoli’s experience in POCT and their strong infrastructure are an excellent complement to our Company, and we look forward to a successful partnership with them.”

About Cremascoli & Iris, s.r.l.

Cremascoli is a well-established company in Italy, specializing in Point of Care Testing, Anesthesia & ICU, and Neonatology & GYN products, providing distribution to hospitals, universities and private clinics throughout all of Italy. The Company has 28 sales reps, covering all regions of Italy and a network of sub-distributors, in addition to nine sales and marketing product and clinical specialists to further develop and support the market.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack and congestive heart failure through our commercial partners, Roche and Shionogi and through select international distributors.

In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.

Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", "goal" and similar expressions, are "forward-looking statements" or "forward-looking information" under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, financial risks that would affect our operations such as our limited available working capital and cash flows and whether and for how long available funds will be sufficient to fund our operations and our ability to raise additional capital as and when needed; our need for substantial additional funding to conduct research and development and commercialization activities; current financial market conditions which may negatively affect our ability to obtain financing; changing facility costs and other risks relating to our facilities expansion plans; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; our ability to obtain and maintain rights to technology from licensors; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; technical risk in research and development; adverse results or unexpected delays in product development and clinical trials; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; our ability to obtain, and the timing of, necessary regulatory approvals; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from others with significantly more resources; market acceptance of our products and the size of our markets; changes in business strategy or development plans; changes in, or the failure to comply with, governmental regulations; fluctuations in interest rates and foreign exchange rates; seasonality including government budget cycles; general economic and business conditions where we operate; and other factors referenced in our annual report, our Annual Information Form (AIF) (Form 20-F in the U.S.) and other filings with Canadian and United States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments, except as required by law.

CONTACT:
Response Biomedical Corporation
Bill Wickson, 604-456-6073
Director, Investor Relations
bwickson@responsebio.com

Exhibit 99.2

FORM 51-102F3

MATERIAL CHANGE REPORT

1. NAME AND ADDRESS OF COMPANY

Response Biomedical Corporation. ("the Company")
1781 – 75Th Avenue W.
Vancouver B.C. V5P 6P2

2. DATE OF MATERIAL CHANGE

January 4, 2011

3. PRESS RELEASE

The Company issued a news release through Business Wire, filed on SEDAR, EDGAR and the Company's Web site, and disseminated to shareholders on January 4, 2011.

4. SUMMARY OF MATERIAL CHANGE

Vancouver, British Columbia, January 4, 2011 – Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that it has entered into an exclusive distribution agreement with Cremascoli & Iris, s.r.l. of Milan, Italy to distribute the full line of RAMP® cardiac products in Italy

5. FULL DESCRIPTION OF MATERIAL CHANGE

Vancouver, British Columbia, January 4, 2011 – Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that it has entered into an exclusive distribution agreement with Cremascoli & Iris, s.r.l. of Milan, Italy to distribute the full line of RAMP® cardiac products in Italy.

Italy is the second largest market in Europe after Germany for cardiac Point of Care Testing (POCT). The Italian market for POCT cardiac products is expected to exceed U.S. $50 million in 2011, and projected to grow at 5% per year through 2015. There are approximately 750 public hospitals and 400 private clinics throughout Italy.

"We are very pleased to be representing the RAMP® cardiac products in Italy," said Andrea Cremascoli, Product Manager, POCT. "Due to the excellent product performance of the RAMP® products, we believe the Italian market offers significant opportunity for product placement and market growth in the coming years."

"We are aggressively working to expand our market presence throughout Europe, the Middle East and Asia, and are delighted that Cremascoli will represent our RAMP® products in Italy," said S. Wayne Kay, CEO, Response Biomedical. "Cremascoli's experience in POCT and their strong infrastructure are an excellent complement to our Company, and we look forward to a successful partnership with them."

6. RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102

Not Applicable

7. OMITED INFORMATION

Not Applicable

8. EXECUTIVE OFFICER

The following executive officer of the Company is knowledgeable about the material change and may be contacted by the Commission at the following telephone number:

Livleen Kaler, VP, Finance & Chief Financial Officer
1781 – 75th Avenue W.
Vancouver, BC V6P 6P2

Telephone: (604) 456-6010
Facsimile: (604) 456-6066

9. DATE OF REPORT

Dated at Vancouver, B.C., this 4th day of January 2011.